The success of kinase inhibitors in treating cancers bearing mutations in kinases has fueled a growing transformation of the cancer drug development enterprise into one informed by cancer genomics. The new mantra, quite simply, is that cancers bearing oncogenic mutations in a kinase are dependent on that kinase for growth and survival. With rare exception, patients with such tumors have derived significant benefit (that is, their tumors shrink) when treated with an inhibitor of that mutant kinase. The probability of success in such patients is so high that drug discovery programs can (and should) be launched when a new kinase mutation is discovered in a subset of human cancers. The drugs that emerge are anticipated to be active as single agents when studied in appropriate patients and can rapidly advance through clinical development. Yet, this may not be the only promising approach to discover new therapeutic targets. In this issue, Luo et al. (2009) and Scholl et al. (2009) report the use of large-scale RNA interference screens to probe the vulnerabilities of cancer cells expressing oncogenic K-RAS.
The confidence born of the success with kinase inhibitors provides much of the rationale for the Cancer Genome Atlas, the national effort to resequence the genomes of several hundred tumors of each major human cancer (Cancer Genome Atlas Research Network, 2008) . Of course, this encyclopedic approach is costly and may yield few new leads. At least one new mutant (and presumably druggable) cancer target, isocitrate dehydrogenase 1 gene (IDH1), has emerged from an independent glioblastoma resequencing project (Parsons et al., 2008) . However, its utility as a drug target remains unclear, given recent evidence suggesting that mutant IDH1 has a tumor suppressor rather than an oncogenic function (Yan et al., 2009) .
The Cancer Genome Atlas also has the broader goal of generating a com-Kinase inhibitors have ushered in the era of targeted therapy, but their utility to date is primarily limited to cancers bearing oncogenic kinase mutations. Two papers in this issue (Luo et al., 2009; Scholl et al., 2009) could change this landscape by uncovering kinase-specific vulnerabilities in tumors with RAS mutations. (A) In the well-by-well approach, the impact of each individual short hairpin RNA (shRNA) on growth or survival is scored after a predefined incubation period. shRNAs that selectively kill cells bearing the mutant oncogene versus wild-type cells (designated by "X") are deemed "hits." Genes targeted across a panel of mutant cell lines and by independent hairpins rank highest on the hit list. The well-by-well approach requires a high-throughput screening infrastructure due to the number of shRNAs in a reasonably comprehensive library and the number of cell lines screened to generate confidence in hits. (B) With the pooled screening approach, cells are infected with the entire pooled shRNA library at a low multiplicity of infection (to assure one shRNA per cell. The cells are then passaged for multiple population doublings to deplete those cells whose growth is adversely impacted by a specific shRNA. The identity of shRNAs that drop out during serial passage (designated by "X") is determined by barcode array hybridization. As with the well-by-well approach, genes targeted by more than one independent shRNAs in multiple cell lines are ranked most highly. Both strategies are limited by an unknown but presumably high "false negative" rate, given that few of the shRNAs in current libraries are validated to confer substantial knockdown.
plete map of all genomic alterations in human cancer. But with rare exceptions, such as IDH1, few discoveries are anticipated to generate immediately actionable drug targets. For common but currently undruggable cancer mutations in oncogenes, such as RAS, and tumor suppressors, such as PTEN and TP53, the Cancer Genome Atlas may provide little translational insight.
One alternative is to screen for synthetic lethality to identify druggable targets that are uniquely required by tumor cells but not normal cells (Kaelin, 2005) . Two general strategies can be envisioned: (1) chemical screens in which compounds are found that specifically kill tumor cells, but these "hits" generally require extensive additional work to define their protein targets, and (2) RNA interference screens in which "hits" immediately define a new drug target that, in some cases, can be aggressively pursued with conventional enzyme-based drug discovery approaches. Pilot studies using both strategies have been reported, but none of the discoveries from these early screens are known to have progressed to drug development programs. Therefore, in contrast to the impressive track record of targets emerging from studies of the human cancer oncogenome, the probability of clinical success with targets emerging from synthetic lethal screens is unknown. Based on two papers in the current issue of Cell, we may get an answer soon.
The two independent teams, led by Gilliland and Elledge respectively, identify two kinases-STK33 (serine/ threonine kinase 33) and PLK1 (pololike kinase 1)-in screens for synthetic lethality using short hairpin RNAs (shRNAs) in human cancer cells expressing mutant K-RAS (Scholl et al., 2009; Luo et al., 2009 ). The translational implications of both reports are important and immediate. K-RAS is among the most commonly mutated human cancer genes, and inhibitors of STK33 and PLK1 should be relatively straightforward to identify via standard chemical approaches. Indeed, preclinical PLK1 inhibitors have already been described (McInnes et al., 2005; Steegmaier et al., 2007) . Clinical trials of such inhibitors in patients with K-RAS mutant tumors could, in principle, begin in 1-2 years.
There are important technical differences between the screens conducted by the two groups that may impact the broader application of shRNA screening by the cancer research community (Figure 1 ). Gilliland and colleagues screened ?5000 shRNAs targeting ?1000 genes across a panel of eight human cancer cell lines (4 K-RAS wild-type and 4 K-RAS mutant) using a well-by-well approach in which the biological effects of each hairpin are scored individually (Scholl et al. 2009 ). Annotation of "hits" that score only across the four K-RAS mutant lines yields a small list of genes that include K-RAS (as expected) and STK33 at the top. Additional studies in several diverse biological systems confirm the synthetic lethal association of STK33 with K-RAS, which, remarkably, appears to be specific for K-RAS and does not extend to H-RAS or N-RAS mutant tumor lines. Furthermore, a few cell lines not previously known to bear K-RAS mutations score as STK33-dependent and are found upon closer inspection to bear previously unappreciated K-RAS mutations at atypical codons. Although clearly powerful, such large-scale well-by-well screening (at least 160,000 wells for a screen limited to 1000 genes run in quadruplicate) requires a high-throughput platform run by specialized personnel. Cost will preclude the academic community from easily expanding this approach to other undruggable cancer mutations as well as scaling it for whole genome screens.
In contrast, Elledge and colleagues use a pooled screening approach whereby a library of ?75,000 shRNAs targeting ?30,000 mRNA transcripts from ?12,000 genes is introduced into a K-RAS mutant cancer cell line as well as an isogenic wild-type KRAS control (Luo et al., 2009 ). shRNAs targeting ?400 genes are selectively depleted from the library (as detected by barcode arrays) in K-RAS mutant cells after multiple population doublings and deemed candidate RAS synthetic lethals. Roughly a quarter of these "hits" were validated in a repeat screen, and a subset of these were then confirmed in another K-RAS mutant isogenic cell line pair, resulting in a list of 77 validated RAS synthetic lethal genes. Perhaps due to the greater scale (whole genome) relative to the Gilliland screen, no single "hit" emerges as an obvious top candidate. Rather, computational analysis of all "hits" reveals increased dependence of K-RAS mutant cells on the mitotic machinery (including the kinase PLK1) and the proteasome. As predicted from the shRNA analysis, K-RAS mutant cells are preferentially killed by clinical drugs, such as paclitaxel, which target mitotic spindle function, and a preclinical PLK1 inhibitor as well as by the proteasome inhibitor bortezomib.
In addition to the translational implications for patients with K-RAS mutant cancers, these reports will spawn a series of investigations by RAS aficionados into why K-RAS mutant cells are dependent on STK33, PLK1, and the long list of other RAS synthetic lethal genes. Curiously, STK33 does not appear to be a component of the RAS signaling pathway and does not, on its own, score as an oncogene in transformation assays. Furthermore, there is no evidence of STK33 mutation or gene amplification in a limited analysis of human cancers. Rather, cells with mutant K-RAS appear to be rewired and, through that process, acquire unique dependence on STK33. It will be important to dissect the temporal and biochemical details of this rewiring, as well as the normal function of STK33. The enhanced dependence of K-RAS mutant cells on basic cellular functions such as the mitotic machinery and on the proteasome is consistent with growing evidence that cancer cells are stressed and must adapt to avoid stress-induced death that typically occurs in normal cells. Indeed, much recent work has established that some cancer cells are poised to die but are rescued by hyperexpression of prosurvival proteins and that this vulnerability can be exploited clinically with Bcl-2 antagonists such as ABT-737 (Cragg et al., 2009; Letai, 2008) .
The ultimate validation of the synthetic lethal screening strategies outlined here will be evidence that patients with K-RAS mutant tumors benefit from treatment with STK33 or PLK1 inhibitors. Unfortunately we won't have the answer for many years. We already know that a few limited but dramatic clinical successes with kinase inhibitors helped launch a large scale assault on the cancer genome to define all cancer mutations. How long do we wait before launching a similar assault to define all cancer cell vulnerabilities?
When animal cells divide, one cell is cleaved into two by the constriction of a cortical ring (Rappaport, 1996) . The ring is made of actin, myosin II, and actin-binding proteins, but the precise mechanism by which it assembles and constricts is still not understood. In the prevalent model for constriction (sometimes called "pure string contraction"), the force for constriction is generated by myosin II motors sliding actin filaments against each other parallel to the cell membrane, contracting the diameter of the ring (Schroeder, 1975) . However, this view has been questioned and alternative arrangements of actin and myosin II have been proposed (Eggert et al., 2006) . It has even been suggested that constriction force could be generated by actin depolymerization rather than myosin II activity (Zumdieck et al., 2007) . In this issue of Cell, Carvalho et al. (2009) investigate the rate of ring constriction (the change of ring diameter over time) during early development of the worm Caenorhabditis elegans, shedding new light on the mechanism of cytokinesis and its scalability with cell size.
Cortical ring constriction rate in a dividing C. elegans embryonic cell is initially constant but decreases once the ring comes in proximity to the midbody, a microtubule-based structure that is formed between the separated chromosomes in the dividing cell. When formation of the midbody is inhibited, ring constriction continues at a constant rate until complete closure. This suggests that a constant rate of constriction is the default behavior that is modified by the midbody.
When early embryos undergo cell division, their cells become progressively smaller. This provides researchers with an opportunity to investigate physical scaling relationships (Wühr et al., 2008) , as it is likely that the biochemistry of the embryo (such as protein levels and modifications) remains relatively constant during early embryogenesis. Carvalho et al. now measure the rate of cytokinesis constriction in C. elegans embryonic cells of different sizes. They find that cleavage rings constrict at a rate that is proportional to their initial diameter-a cell with twice the diameter constricts twice as fast. As a result of this proportionality, the time it takes to execute cytokinesis remains mostly constant over a wide range of cell sizes. Because the rate of ring contraction is constant once initiated, and larger cells have a faster rate of constriction, the authors interpret this data as showing that cortical rings somehow "memorize" their initial circumference and use that memory to control the rate of constriction throughout cytokinesis. As the ring is an assembly of cytoskeletal proteins, the authors further hypothesize that this memory is encoded in the structure of the initial ring.
How might such a structural memory be achieved? One explanation is that the number of myosin II molecules recruited to the cortical ring is proportional to the initial ring diameter. As the ring constricts, the motors stay bound to the ring. One
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